Detalhe da pesquisa
1.
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell
; 185(12): 2116-2131.e18, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35662412
2.
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Cell
; 185(14): 2422-2433.e13, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772405
3.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Cell
; 184(9): 2348-2361.e6, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730597
4.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Cell
; 184(8): 2201-2211.e7, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743891
5.
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell
; 184(11): 2939-2954.e9, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852911
6.
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Cell
; 184(16): 4220-4236.e13, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34242578
7.
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Nat Immunol
; 24(7): 1161-1172, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37322179
8.
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
Nature
; 586(7830): 578-582, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731258
9.
A bivalent Adenovirus-Vectored Vaccine induces a robust humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus.
J Infect Dis
; 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38487996
10.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1885-1898, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33725432
11.
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Clin Infect Dis
; 76(2): 201-209, 2023 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36196614
12.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Lancet
; 399(10342): 2212-2225, 2022 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691324
13.
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Lancet
; 399(10324): 521-529, 2022 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074136
14.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34883053
15.
ChAdOx1 nCoV-19 vaccination generates spike-specific CD8+ T cells in aged mice.
Immunol Cell Biol
; 101(6): 479-488, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36975169
16.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729167
17.
Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients.
PLoS Pathog
; 17(9): e1009804, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529726
18.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
19.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
; 398(10318): 2258-2276, 2021 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34863358
20.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet
; 398(10303): 856-869, 2021 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34370971